Luke Gill, VP, Head Global Oncology, brings more than 25 years of leadership experience spanning global clinical development, operations and strategic partnerships across the biotech and CRO sectors.

He has successfully built and scaled oncology organizations, leading programs from first-in-human and translational studies through PoC to pivotal Phase III trials and regulatory submissions.

Luke holds an MSc in Neuro and Molecular Pharmacology and an MBA, combining deep scientific understanding with strong financial and commercial leadership.

He has held senior executive positions within international CROs, where he was responsible for multi-regional oncology portfolios, operational excellence programs and strategic alliances with leading biotech and pharmaceutical partners across the USA, Europe and Asia-Pacific (including China). His leadership has driven measurable gains in clinical readouts, delivery quality and biotech satisfaction.